Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. QNCX
stocks logo

QNCX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.180
-35.71%
--
--
-0.185
-45.59%
--
--
-0.188
-44.85%
Estimates Revision
Stock Price
Go Up
up Image
+123.60%
In Past 3 Month
Wall Street analysts forecast QNCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNCX is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast QNCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNCX is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.600
sliders
Low
6.00
Averages
8.00
High
10.00
Current: 3.600
sliders
Low
6.00
Averages
8.00
High
10.00
Citizens JMP
Outperform
downgrade
$9 -> $8
2025-08-12
Reason
Citizens JMP
Price Target
$9 -> $8
2025-08-12
downgrade
Outperform
Reason
Citizens JMP lowered the firm's price target on Quince Therapeutics to $8 from $9 and keeps an Outperform rating on the shares. The firm is impressed with management's execution in completing enrollment for the pivotal NEAT trial, which is set up for success, the analyst tells investors in a research note.
Citizens JMP
Outperform
initiated
$9
2025-08-05
Reason
Citizens JMP
Price Target
$9
2025-08-05
initiated
Outperform
Reason
Citizens JMP initiated coverage of Quince Therapeutics with an Outperform rating and $9 price target. The firm says Quince is using its Autologous Intracellular Drug Encapsulation platform to treat rare diseases using a patient's own biology. The company's lead candidate eDSP offers a blockbuster opportunity with limited competition, the analyst tells investors in a research note. Citizens believes pipeline expansion at Quince could move quickly and drive additional share upside.
Lucid Capital
Elemer Piros
initiated
$8
2025-07-15
Reason
Lucid Capital
Elemer Piros
Price Target
$8
2025-07-15
initiated
Reason
Lucid Capital analyst Elemer Piros initiated coverage of Quince Therapeutics with a Buy rating and $8 price target. The company is developing chronic steroid treatments for rare diseases with "blockbuster potential," the analyst tells investors in a research note. The firm believes the company's EryDex is set to become a blockbuster treatment in the lead ataxia-telangiectasia indication alone.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$12 → $4
2025-03-25
Reason
D. Boral Capital
Jason Kolbert
Price Target
$12 → $4
2025-03-25
Maintains
Strong Buy
Reason
Oppenheimer
Leland Gershell
Buy
Initiates
$10
2025-03-24
Reason
Oppenheimer
Leland Gershell
Price Target
$10
2025-03-24
Initiates
Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$12
2025-02-05
Reason
D. Boral Capital
Jason Kolbert
Price Target
$12
2025-02-05
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Quince Therapeutics Inc (QNCX.O) is -4.82, compared to its 5-year average forward P/E of -4.74. For a more detailed relative valuation and DCF analysis to assess Quince Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.74
Current PE
-4.82
Overvalued PE
2.98
Undervalued PE
-12.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.66
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.32
Undervalued EV/EBITDA
-9.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

QNCX News & Events

Events Timeline

(ET)
2025-11-12
16:20:57
Quince Therapeutics announces Q3 earnings per share of 25 cents, surpassing consensus estimate of 22 cents.
select
2025-11-10 (ET)
2025-11-10
16:11:23
Quince Therapeutics Reports Favorable iDSMB Evaluation for eDSP in Phase 3 Trial
select
2025-08-11 (ET)
2025-08-11
16:09:54
Quince Therapeutics reports Q2 EPS (34c), consensus (23c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
12-01NASDAQ.COM
Monday's Underperforming Sectors: Biotechnology, Electronic Equipment, and Products

  • Market Performance: Electronic equipment and products shares are down approximately 2.3% on Monday, with notable declines from ESS Tech and Hyperscale Data, which fell by 10.9% and 8.4%, respectively.

  • Sector Laggards: The biotechnology sector is also highlighted as a laggard alongside electronic equipment and products in the market on Monday.

  • Author's Perspective: The views expressed in the article are solely those of the author and do not necessarily represent the opinions of Nasdaq, Inc.

  • Video Content: A video segment is mentioned that discusses the sector laggards, specifically focusing on biotechnology and electronic equipment and products.

[object Object]
Preview
1.0
09-12Newsfilter
Quince Therapeutics to Hold Virtual Investor Day on October 2, 2025

  • Investor Day Announcement: Quince Therapeutics will host a virtual Investor Day on October 2, 2025, featuring presentations on their innovative AIDE technology and updates on clinical trials, particularly for Ataxia-Telangiectasia (A-T).

  • Clinical and Regulatory Insights: The event will cover the company's pivotal Phase 3 NEAT trial for eDSP, regulatory agreements with the FDA, and the potential for expanding their treatment pipeline into other rare diseases like Duchenne muscular dystrophy.

[object Object]
Preview
4.0
08-05Benzinga
This Lionsgate Studios Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

  • Analyst Ratings Updates: Several Wall Street analysts have initiated coverage on various companies, including Lionsgate Studios (Overweight rating, $9 target), MBX Biosciences (Outperform rating, $38 target), D-Wave Quantum (Buy rating, $26 target), APA Corporation (Equal-Weight rating, $24 target), and Quince Therapeutics (Market Outperform rating, $9 target).

  • Stock Performance: The current closing prices for these stocks are significantly lower than the analysts' price targets, with Lionsgate at $5.99, MBX at $12.54, D-Wave at $17.18, APA at $18.27, and Quince at $1.63.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Quince Therapeutics Inc (QNCX) stock price today?

The current price of QNCX is 3.6 USD — it has increased 2.27 % in the last trading day.

arrow icon

What is Quince Therapeutics Inc (QNCX)'s business?

Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.

arrow icon

What is the price predicton of QNCX Stock?

Wall Street analysts forecast QNCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNCX is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Quince Therapeutics Inc (QNCX)'s revenue for the last quarter?

Quince Therapeutics Inc revenue for the last quarter amounts to -11.36M USD, increased 32.97 % YoY.

arrow icon

What is Quince Therapeutics Inc (QNCX)'s earnings per share (EPS) for the last quarter?

Quince Therapeutics Inc. EPS for the last quarter amounts to -10002000.00 USD, increased 36.90 % YoY.

arrow icon

What changes have occurred in the market's expectations for Quince Therapeutics Inc (QNCX)'s fundamentals?

The market is revising No Change the revenue expectations for QNCX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 123.60%.
arrow icon

How many employees does Quince Therapeutics Inc (QNCX). have?

Quince Therapeutics Inc (QNCX) has 36 emplpoyees as of December 05 2025.

arrow icon

What is Quince Therapeutics Inc (QNCX) market cap?

Today QNCX has the market capitalization of 200.45M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free